Enable Injections Expands Strategic Partnership with Roche
07 Mayo 2024 - 6:30AM
Enable Injections, Inc. ("Enable"), a leading
innovator in developing and manufacturing the enFuse® platform of
wearable drug delivery device technology, today announced the
Company has expanded its partnership with Roche through a
collaboration, allowing Roche to develop and apply Enable’s
expertise and enFuse delivery technology to specific Roche
development programs. Through this collaboration, Roche will obtain
a worldwide, exclusive license to develop and commercialize
combinations of the enFuse technology with specific Roche
molecules. Enable will be responsible for clinical and commercial
manufacturing and supply of the enFuse system.
enFuse is the first purely mechanical wearable drug delivery
device technology designed to deliver large volumes of small
molecule and biologic medications subcutaneously, whereby patients
receive their needed treatment in a simple injection under the
skin, instead of intravenously.
“IV infusions can be inconvenient and time-consuming for both
patients and providers. This is especially true when treating
chronic disorders, which require longer-term treatment and frequent
trips to the clinic,” said Mike Hooven, Chairman and CEO of Enable
Injections. “enFuse was designed to overcome IV infusion
shortcomings through fast, simple and convenient delivery, bringing
efficiency and value to the entire spectrum of healthcare,
including patients, providers, and payers, with the ability for at
home self-administration.”
“We are pleased that Roche recognizes the significant value our
wearable technology brings to the patient treatment experience and
look forward to serving patients through the potential of our
differentiated device delivery platform with Roche’s differentiated
molecules,” continued Hooven.
About Enable InjectionsCincinnati-based Enable
Injections is a global healthcare innovation company developing and
manufacturing drug delivery systems designed to improve the patient
experience. Enable's body-worn enFuse® delivers high-volume
pharmaceutical and biologic therapeutics via subcutaneous
administration, with the aim of improving convenience, supporting
superior outcomes, and advancing healthcare system economics.
Approved in the United States in combination with a specific drug,
more
information: https://enableinjections.com/our-products.
Enable is currently working with a number of pharmaceutical
partners to conduct clinical trials and plan for joint commercial
launch of their therapies in combination with the enFuse
technology. The Company continues to selectively add to its list of
pharmaceutical partners, with indications and patient populations
who will benefit from the enFuse system. The first enFuse
combination product received U.S. FDA approval in 2023.
Media ContactSheryl SeapyReal Chemistry
sseapy@realchemistry.com